TNFRSF9 and small cell lung carcinoma: Durvalumab with olaparib (NCT02734004, MENDIOLA), avelumab with utomilumab, which is a humanized monoclonal antibody (mAb) that stimulates signaling through CD137 (NCT02554812), nivolumab plus ipilimumab with dendritic cell-based p53 vaccine 9 (NCT03406715) in relapsed SCLC, atezolizumab with chemotherapy and a CDK 4/6 inhibitor trilaciclib (NCT03041311) in first-line ES-SCLC are some of the novel combinations of immunotherapy with targeted agents.